Cancer chemotherapy for uric acid degrading enzyme preparation Rasburicase is an effective drug as a treatment and prophylactic for tumor lysis syndrome (TLS). It exerts a rapid uric acid reduction effect by its powerful uric acid oxidation action. Details such as uric acids and electrolytes after completion of the drug administration have not been studied, though re-rise of the uric acid, and uric acid levels have not been reported as risk factors for re-increase. In this study, adult hematologic malignancies patients treated with Rasburicase for TLS prophylactic purposes after cancer chemotherapy were classified into a drug increment of uric acid group and no increment of uric acid group. We investigated the risk factors for increment of uric acid and examined the daily dose of Rasburicase, administration period, TLS risk classification, serum phosphorus, potassium, calcium values before administration. There was a significant difference between the two groups, and the multiple logistic regression analysis showed that the daily dosage and administration period of Rasburicase were significant. These results indicate that the dosage and administration period should be carefully considered when re-administering Rasburicase.

